Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent.
| Autor: | Thakral P; Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, Haryana, India., Sen IB; Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, Haryana, India., Das SS; Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, Haryana, India., Schultz MK; Division of Nuclear Medicine, University of Iowa, Iowa, IA, USA., Kumari J; Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, Haryana, India., Virupakshappa CB; Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, Haryana, India., Malik D; Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, Haryana, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India [Indian J Nucl Med] 2024 Mar-Apr; Vol. 39 (2), pp. 142-143. Date of Electronic Publication: 2024 May 29. |
| DOI: | 10.4103/ijnm.ijnm_2_23 |
| Abstrakt: | Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC. Competing Interests: There are no conflicts of interest. (Copyright: © 2024 Indian Journal of Nuclear Medicine.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|